Celcuity Inc. (CELC) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Minneapolis, MN, United States. El CEO actual es Brian F. Sullivan.
CELC tiene fecha de IPO 2017-09-20, 87 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $5.84B.
Celcuity Inc. is a clinical-stage biotechnology company headquartered in Minneapolis, Minnesota, focused on developing molecularly targeted cancer therapies for patients in the United States. The company's proprietary CELsignia diagnostic platform analyzes living tumor cells to identify the specific cellular abnormalities driving a patient's cancer and determines the most appropriate targeted treatment approach. Its lead drug candidate, Gedatolisib, selectively targets PI3K and mTOR pathways and is being evaluated for treating hormone receptor-positive, HER2-negative advanced or metastatic breast cancer under a license agreement with Pfizer. Celcuity is also advancing the CELsignia MP test, a laboratory-developed diagnostic that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor samples to guide therapeutic selection.
